India-based Cipla has introduced Serroflo (salmeterol/fluticasone MDI) in Germany and Sweden to treat patients suffering from asthma.

Serroflo is expected to improve the affordability of fixed combinations in Europe and help manage health costs for respiratory treatment.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Cipla Europe head Frank Pieters said: "With Serroflo, we offer in Germany and Sweden an alternative, which is effective and efficient and therefore brings many advantages into a market, which suffers from limited resources."

"Serroflo is expected to improve the affordability of fixed combinations and help manage health costs for respiratory treatment."

The new product is available under the name Serroflo in Germany, while it is introduced as Salmeterol/Fluticasone Cipla in Sweden.

Both are available in a pMDI with HFA propellant in two strengths, 120 doses of 25/125mcg salmeterol/fluticasone and 120 doses of 25/250mcg salmeterol/fluticasone.

The combination is already available under the name Duohal in Europe, apart from Croatia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cipla managing director and global CEO Subhanu Saxena said: "Over the next 12-18 months we will see a series of launches throughout Europe as we know that there is a common need for high quality, affordable, reliable and thus sustainable therapy-alternatives."

As per the ERS Lung white book 2013, around 30 million people under 45 years suffer from asthma in Europe.

Cipla produces around 2,000 products in 65 therapeutic categories and sells its products in approximately 100 countries.